相关实验视频
Updated: Jul 26, 2026
11:29
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
10.9K
关于长非编码RNA作为前列腺癌新兴诊断和治疗点的分析的最新评论
Zongpan Ke1, Xuechun Hu2, Yixun Liu2
1Department of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, No. 17 Lujiang Road, Luyang District, Hefei 230001, China; Wannan Medical College, No. 22 Wenchangxi Road, Yijiang District, Wuhu 241000, China.
Critical reviews in oncology/hematology
|February 1, 2024
概括
长非编码RNAs (lncRNAs) 是前列腺癌 (PCa) 进展的关键参与者,影响转移和治疗抵抗. 了解lncRNA的作用为这种具有挑战性的疾病提供了新的诊断和治疗途径.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 前列腺癌 (PCa) 仍然是全球主要的健康问题,经常被诊断为晚期,并表现出治疗耐药性.
- 长非编码RNAs (lncRNAs) 越来越多地被认为对癌症的发展和进展起作用.
研究的目的:
- 审查 lncRNAs 在前列腺癌进展中的复杂作用.
- 探索异常lncRNA表达如何影响PCa特征和治疗耐药性.
- 讨论 lncRNAs 在PCa.中作为诊断和治疗点的潜力.
主要方法:
- 文献综述侧重于前列腺癌中的lncRNAs.
- 对调节基因表达和信号通路的lncRNA机制的分析.
- 对PCa中的lncRNAs当前研究的批判性评估.
主要成果:
- 异常的lncRNA表达与进展性PCa中增加的增殖,入侵和转移有关.
- lncRNAs影响关键的分子效应因子,包括转录因子和microRNAs,影响诸如雄激素受体信号传导之类的途径.
- lncRNAs呈现新的机制,驱动PCa的进展和对治疗的抗性.
结论:
- lncRNAs是前列腺癌进展和治疗耐药性的关键调节者.
- 了解lncRNA的功能,可以了解PCa的病原性.
- lncRNAs作为诊断的生物标志物和PCa的治疗点具有显著的前景.
更多相关视频
相关概念视频
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...